Home Tags Pfizer

Tag: Pfizer

PF 06263507: Targeting Treatment-resistant Childhood Leukemia

Researchers at The University of Manchester have discovered that 5T4, a transmembrane glycoprotein overexpressed by a variety of cancers and correlated with increased invasiveness,...

Trial of High Efficiency TFF Capsule Prototype for ADC Purification

Antibody-drug conjugates (ADCs) are an emerging class of highly targeted cancer therapies in which a monoclonal antibody is chemically conjugated to a cytotoxic drug...

Pfizer Resubmits Application for Gemtuzumab Ozogamicin to European and American Regulators

In late January 2017 Pfizer's Biologics License Application (BLA) for gemtuzumab ozogamicin (Mylotarg®; previously known as CMA-676) was accepted for filing by the U.S....
Drugs & Durg Hunters

Drugs and Drug Hunters

All products of the creative process are a reflection of the individual makeup of the inventors.  A painting by Mark Rothko looks like a...

London Calling: The Cutting-edge of Novel ADC Technologies

Major players in the rapidly advancing field of antibody drug conjugates (ADCs) will meet in London, United Kingdom, on 23-24 May for the annual...

Breakthrough Therapy Designation for Sacituzumab Govitecan in Triple-negative Breast Cancer

Sacituzumab govitecan, also known as IMMU-132, has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the treatment of patients...

Pfizer Exercises Options As Part of License Agreement with Philogen

Swiss-Italian Philogen, a clinical-stage biotechnology company engaged in the discovery and development of novel biopharmaceutical products, has confirmed that Pfizer has exercised options granted...

New Anticancer Drugs Show Promise in the Treatment of Solid Tumors

A number of novel anticancer drugs are showing very promising results in the treatment of solid cancers. These cancers, including various forms of lung cancers,...

Pfizer and Philogen Develop & Commercialize Antibody-drug Conjugates

Philogen, a Swiss-Italian clinical-stage biotechnology company based in Sienna, Italy, engaged in the discovery and development of novel biopharmaceutical products including antibodies and small molecule targeted...

University of Virginia Spin-off Neoantigenics Signs Agreement with Pfizer

Neoantigenics, a privately held oncology biotechnology company located in Charlottesville, established in July 2012 by John Herr at the University of Virginia School of Medicine, to...